Functional neuroimaging technique using radioactive glucose analog (18F-fluorodeoxyglucose) to visualize metabolic activity in tissues by detecting positron emission from trapped, phosphorylated FDG molecules. Particularly valuable for mapping neural activity patterns, detecting neuroinflammation, and identifying altered metabolic states in brain regions involved in Immunoception, interoception, and chronic disease processes.
Think of FDG-PET like sending glow-in-the-dark sugar particles through a factory to see which departments are working overtime. Your cells grab glucose like workers grabbing lunch boxes—but FDG is a trick lunch box. It gets picked up by the same transport trucks (GLUT1, GLUT4), carried inside, and even partially unpacked (phosphorylated by hexokinase). But then it gets stuck—it can't be metabolized further, like a lunch box with a lock that won't open. It just sits there, glowing radioactively, accumulating in whichever departments are hungriest. In the brain, the busiest neurons and activated immune cells (Microglia, infiltrating leukocytes) grab the most FDG. The scanner detects the radioactive glow and maps which brain regions (or inflammatory hotspots) are metabolically hyperactive. A depressed person might show a dim prefrontal cortex (low energy expenditure in executive control), while someone with GAD-antibody spectrum disorders might show bright spots in the insula or limbic system where autoimmune inflammation is raging.
FDG is a fluorine-18 labeled glucose analog with a hydroxyl group replaced by ¹⁸F at the 2-position. The imaging cascade proceeds as follows:
Cellular uptake: FDG enters cells via glucose transporters (primarily GLUT1 in brain neurons and glia; GLUT4 in insulin-sensitive tissues like muscle). Active immune cells upregulate GLUT1 during activation.
Phosphorylation: Hexokinase phosphorylates FDG to FDG-6-phosphate, consuming one ATP. This step is identical to glucose metabolism.
Metabolic trapping: Unlike glucose-6-phosphate, FDG-6-phosphate cannot be further metabolized by phosphoglucose isomerase (lacks a hydroxyl group at C-2). It becomes trapped intracellularly for ~110 minutes (¹⁸F half-life).
Radioactive decay: ¹⁸F undergoes β⁺ decay (positron emission). Emitted positrons travel 1-2mm, collide with electrons, and annihilate, producing two 511-keV photons at 180° angles.
Detection and imaging: PET scanner detects coincident photon pairs, reconstructing spatial distribution of FDG accumulation. High signal indicates high metabolic demand.
In neuroinflammation, activated Microglia shift to Aerobic Glycolysis (Warburg Effect), dramatically increasing Glucose uptake despite oxygen availability. This makes FDG-PET highly sensitive to immune activation in the brain. Peripheral immune cells (macrophages, neutrophils) similarly show elevated FDG uptake when activated, enabling detection of systemic inflammatory foci.
FDG-PET provides objective visualization of brain metabolic dysfunction in conditions central to cPNI practice:
Neuroinflammation and autoimmunity: In GAD-antibody spectrum disorders (stiff person syndrome, cerebellar ataxia, limbic encephalitis), FDG-PET reveals hypermetabolic regions where autoimmune attack is active—often the insula, Amygdala, Hippocampus, or cerebellum. This allows differentiation between structural damage (MRI lesions) and active metabolic dysfunction. Threshold: >15-20% asymmetry in regional uptake suggests pathology.
Depression and chronic fatigue: Depression classically shows prefrontal hypometabolism (reduced glucose uptake in Prefrontal cortex, particularly dorsolateral and ventromedial regions) and limbic hypermetabolism (Amygdala, subgenual ACC). This maps onto the Selfish brain theory—the depressed brain is metabolically constrained, prioritizing survival circuits over executive function. Chronic fatigue syndrome may show Hypothalamic Inflammation and altered salience network activity.
Chronic pain: chronic pain patients show increased FDG uptake in pain processing regions: insular cortex, anterior cingulate cortex, thalamus, somatosensory cortex. This demonstrates central sensitization at a metabolic level. The insula's role in interoception and Immunoception is particularly relevant—increased insular metabolism suggests heightened processing of bodily threat signals.
Immunoception mapping: FDG-PET can visualize the Immune Homunculus—brain regions that respond to peripheral inflammation. During immune challenges (e.g., LPS injection, vaccination), FDG uptake increases in the insula, ACC, Hypothalamus, and Brainstem nuclei (nucleus tractus solitarius, area postrema). This provides direct evidence for immune-to-brain signaling.
Metabolic flexibility assessment: Sequential FDG-PET scans (fasted vs. fed) can demonstrate Metabolic flexibility—whether brain regions can switch between glucose and ketone utilization. Rigid glucose dependence suggests mitochondrial dysfunction.
Treatment monitoring: FDG-PET tracks response to interventions. Anti-inflammatory protocols should normalize hypermetabolic inflammatory regions. Psychotherapy may increase prefrontal metabolism in depression. Failed normalization indicates treatment resistance or inadequate intervention.
Evolutionary context: The brain's obligate glucose dependence (unlike muscle, which can use fatty acids) reflects evolutionary pressure for continuous neural function. FDG-PET reveals when this system fails—when the selfish-brain cannot extract sufficient glucose (hypometabolism) or when inflammatory competition for glucose disrupts allocation (Aerobic Glycolysis by immune cells).